Landipirdine - Acorda Therapeutics

Drug Profile

Landipirdine - Acorda Therapeutics

Alternative Names: RO-5025181; RO5025181-000; SYN-120

Latest Information Update: 28 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Acorda Therapeutics
  • Class Antiparkinsonians; Nootropics; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists; Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Cognition disorders

Highest Development Phases

  • Discontinued Cognition disorders; Parkinson's disease

Most Recent Events

  • 28 Sep 2018 Discontinued - Phase-I for Cognition disorders in USA (PO)
  • 28 Sep 2018 Discontinued - Phase-II for Parkinson's disease in USA (PO)
  • 22 Mar 2018 Acorda Therapeutics has patent protection for landipiridine in USA and European union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top